Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Keith Thomas Flaherty, M.D.

Co-Author

This page shows the publications co-authored by Keith Flaherty and Hensin Tsao.
Connection Strength

2.636
  1. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. J Invest Dermatol. 2021 Aug; 141(8):2018-2027.e4.
    View in: PubMed
    Score: 0.240
  2. Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. J Invest Dermatol. 2021 May; 141(5):1317-1324.e1.
    View in: PubMed
    Score: 0.234
  3. Selective uveal melanoma inhibition with calcium channel blockade. Int J Oncol. 2019 Nov; 55(5):1090-1096.
    View in: PubMed
    Score: 0.216
  4. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. . 2016 07 02; 17(7):778-84.
    View in: PubMed
    Score: 0.173
  5. Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. J Invest Dermatol. 2016 05; 136(5):1002-1011.
    View in: PubMed
    Score: 0.169
  6. Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. Melanoma Manag. 2015 May; 2(2):133-147.
    View in: PubMed
    Score: 0.160
  7. MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol. 2015 Jul; 135(7):1863-1872.
    View in: PubMed
    Score: 0.158
  8. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 2015 Mar; 5(3):274-87.
    View in: PubMed
    Score: 0.156
  9. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Semin Cutan Med Surg. 2014 Jun; 33(2):60-7.
    View in: PubMed
    Score: 0.150
  10. Commentary: Molecular testing in melanoma. J Am Acad Dermatol. 2014 May; 70(5):863-70.
    View in: PubMed
    Score: 0.147
  11. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res. 2013 Aug 15; 19(16):4383-91.
    View in: PubMed
    Score: 0.141
  12. Melanoma: new insights and new therapies. J Invest Dermatol. 2012 Mar; 132(3 Pt 2):854-63.
    View in: PubMed
    Score: 0.127
  13. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol. 2012 Feb; 132(2):356-64.
    View in: PubMed
    Score: 0.125
  14. Targeting the RAS pathway in melanoma. Trends Mol Med. 2012 Jan; 18(1):27-35.
    View in: PubMed
    Score: 0.125
  15. Molecular therapeutic approaches to melanoma. Mol Aspects Med. 2010 Apr; 31(2):194-204.
    View in: PubMed
    Score: 0.111
  16. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 05 15; 27(10):2678-2697.
    View in: PubMed
    Score: 0.059
  17. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 07; 29(4):404-16.
    View in: PubMed
    Score: 0.043
  18. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar; 5(3):264-73.
    View in: PubMed
    Score: 0.039
  19. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. . 2013 Jul; 12(7):1171-9.
    View in: PubMed
    Score: 0.035
  20. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 01; 70(13):5213-9.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.